The US biotech’s LOXL2 inhibitor candidate has reduced collagen fibrosis of the bone marrow in a small number of Phase II patients, helping validate a historically tricky approach attempted by few.

The Medtech Mandate, a scheme that seeks to better match NICE guidance with adoption and use of medtech innovations in the UK, is preparing for launch in April.

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Two preclinical antibodies targeted at stromal biology-associated immuno-oncology processes from Canada’s Northern Biologics have been acquired by Boehringer Ingelheim, which is also to collaborate with Switzerland’s CDR-Life on the development of a preclinical antibody fragment aimed at geographic atrophy associated with age-related macular degeneration.